TIDMGPL
RNS Number : 4655W
Graft Polymer (UK) PLC
18 August 2022
This announcement contains inside information for the purposes
of Article 7 of EU Regulation No. 596/2014, which forms part of
United Kingdom domestic law by virtue of the European Union
(Withdrawal) Act 2018 (as amended).
18 August 2022
Graft Polymer (UK) Plc
("Graft Polymer", the "Company", and together with its
subsidiaries, the "Group")
First Commercial Purchase Order Received for GraftBio
Division
Graft Polymer (UK) Plc (LSE: GPL), a business focused on the
development and commercial production of polymer modification,
biological supplements, and nano-drug delivery systems, is pleased
to announce the receipt of a first material commercial purchase
order to the Group's GraftBio division for an anti-inflammatory
supplement to be sold in the USA.
Key Highlights:
-- Purchase order to supply 50,000 units of ArtemiC(TM) Rescue
received from MGC Pharmaceuticals Plc ('MGC Pharma')
-- First large commercial purchase order received by GraftBio
-- Production will commence immediately, with delivery of
ArtemiC(TM) Rescue products to MGC Pharma, and associated funds
remitted to Graft Polymer, expected over the next three months
-- The US$1 million Purchase Order for 50,000 units of
ArtemiC(TM) Rescue received by MGC Pharma from US based AMC
Holdings, Inc. ('AMC')
-- On successful delivery of the ArtemiC(TM) Rescue products to
AMC, there is potential for follow-on purchase orders and future
revenue streams from future demand from their US distribution
network
-- ArtemiC(TM) Rescue is a nutraceutical which, in a Phase II
Clinical Trial undertaken in 2020, demonstrated a range of benefits
for patients suffering from moderate COVID-19.
-- Graft Polymer have licenced its drug delivery system platform
to MGC Pharma to deliver active ingredients more effectively to
improve the bioavailability and synergy of the natural
ingredients
Victor Bolduev, CEO, commented, " This near-term revenue
generating purchase order from MGC Pharma is a significant moment
for Graft Polymer, and one which we anticipate follow-on orders
from in the coming quarters. The ability for the GraftBio
proprietary drug delivery system division to licence and produce a
wide range of products for pharmaceutical clients like MGC Pharma,
and many other customers and industries going forward, demonstrates
the diverse nature of our technology.
"With cash on hand and having recently reached cash flow
positive status at the Slovenian facility through organic growth
alone, this first commercial purchase order, along with the
continuous operational developments being made, puts Graft Polymer
in a strong position as we continue to deliver on our
strategy."
Further Information
In 2020, Graft Polymer launched a new division named GraftBio to
develop IP for Bio/Pharma applications. This includes a drug
delivery system ('DDS') to support and provide solutions to the
market, which had been heavily impacted by the COVID-19 pandemic.
The Group has developed a set of DDS's that enable it to licence
its DDS platform (IP) to MGC Pharma in relation to a number of
MGC's products, including ArtemiC(TM) Rescue. ArtemiC(TM) Rescue is
a nutraceutical which, in a Phase II Clinical Trial undertaken in
2020 using Swiss PharmaCan AG's award winning MyCell(TM)
technology, demonstrated a range of benefits for patients suffering
from moderate COVID-19. Following the study, Graft Polymer have
licenced the drug delivery system platform to MGC Pharma for the
delivery of active ingredients to more effectively improve the
bioavailability and synergy of the natural ingredients.
Following a US$1 million purchase order to MGC Pharma for 50,000
units of its ArtemiC(TM) Rescue product, Graft Polymer, via the
Group's GraftBio division, has received its first commercial
purchase order for the 50,000 units of ArtemiC(TM) Rescue.
Production of the 50,000 units of ArtemiC(TM) Rescue will
commence immediately and delivery to MGC Pharma, and associated
funds remitted to Graft Polymer, will be made over the next three
months.
If the delivery by Graft Polymer of 50,000 ArtemiC(TM) Rescue
units is successful, as anticipated, the expectation is further
orders will be received which will have a material positive impact
on future revenues.
**ENDS**
For more information, please visit https://www.graftpolymer.com
or contact:
Graft Polymer (UK) Plc via St Brides Partners
Roby Zomer, Chairman
Yifat Steuer, CFO
Turner Pope Investments (Broker) +44 20 3657 0050
James Pope
Andy Thacker
St Brides Partners (Public Relations)
Catherine Leftley graftpolymer@stbridespartners.co.uk
Ana Ribeiro
Max Bennett
About Graft Polymer
Graft Polymer is a London Stock Exchange listed company (GPL.L)
with a cutting-edge, cash-flow positive, research and development
(R&D) and manufacturing facility based in Slovenia which has
already introduced more than 50 products to the market. The core
business of the Group comprises polymer modification and drug
delivery system developments. The Group has developed a proprietary
set of polymer modification technologies which uses recycled raw
materials and a closed loop system to reduce waste. Graft Polymer's
technology can improve existing products and processing
methodologies by enhancing performance, simplifying manufacturing,
reducing material consumption, widening the choice of feedstocks,
and reducing costs.
Graft Polymer has three divisions: the first division focusses
on polymer modification; the second is GraftBio which develops IP
for Bio/Pharma applications (including a drug delivery system to
support and provide solutions to the market, which had been heavily
impacted by the COVID-19 pandemic); and the third is the Group's
food supplement division. A significant milestone was reached in
May 2022 when the Slovenian manufacturing facility was granted a
Hazard Analysis and Critical Control Point (HACCP) Certificate. The
HACCP Certificate allows it to enter the lucrative
Business-to-Consumer market and commercialise its IP for bio/pharma
applications, developing active pharmaceutical ingredients and drug
delivery platforms for use in the food supplement market, thereby
introducing a further revenue stream to its business.
Environment, Social and Governance is at the forefront of the
Group's strategy and the facility in Slovenia has been granted ISO
14001 accreditation in recognition of the environmental management
systems in place to reduce waste. Graft Polymer only uses REACH and
ROHS certificated raw materials instead of toxic raw materials, and
its extensive R&D programme has also developed specialised
recycling polymer additives which increases the strength of
recycled blends and plastic products whilst also reducing plastic
waste by between 40 and 50 per cent.
Graft Polymer is well funded and debt free.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFFSAAEESEIA
(END) Dow Jones Newswires
August 18, 2022 05:00 ET (09:00 GMT)
Graft Polymer (uk) (LSE:GPL)
Historical Stock Chart
From Apr 2024 to May 2024
Graft Polymer (uk) (LSE:GPL)
Historical Stock Chart
From May 2023 to May 2024